US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.37

+0.01270.05%

Post-market: 27.500.1304+0.48%16:10 EDT

Volume:1K

Turnover:32.81K

Market Cap:2.46M

PE:- -

High:27.50

Open:27.40

Low:27.37

Close:27.36

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:3.97

T/O Rate:1.33%

Dividend:0.45

Dividend Rate:1.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Cryoport Reports Second Quarter 2026 Financial Results

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading

MT Newswires Live

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Corbus reports last patient completes last visit in CANYON-1 trial

IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026

Fresenius announces FDA approval of rituximab biosimilar

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

Press Release: Design Therapeutics Provides Restore-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Recce Pharmaceuticals Seeks ASX Quotation for Advisory Fee Shares

Press Release: Radiopharm Theranostics Reports Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/NVIB/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.3696,"timestamp":1789156800000,"preClose":27.3569,"halted":0,"volume":1193,"hourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"delay":0,"changeRate":0.000464233886149338,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.0127,"latestTime":"09-11 16:00:00 EDT","open":27.401,"high":27.5,"low":27.3696,"amount":32812,"amplitude":0.004767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.3569,"nav":27.337,"aum":2460334.39,"dividendRate":0.016467,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"volumeRatio":3.974015203722743},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.974015203722743,"shares":90001,"dividePrice":0.4507,"high":27.5,"amplitude":0.004767,"preClose":27.3569,"low":27.3696,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.3696,"eps":0,"divideRate":0.016467,"volume":1193,"delay":0,"ttmEps":0,"open":27.401,"prevYearClose":25,"prevWeekClose":28.8896,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.4889,"twentyDayClose":28.3265},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657945657","title":"Press Release: Cryoport Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657945657","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657945657?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Second quarter revenue grew 8% year-over-year to $49.0 million. -- Life Sciences Services revenue increased 15% year-over-year. -- Supporting 779 global clinical trials and 22 commercially approved cell","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","MEDX","03160","HYLG","IDNA","NVIB","GDOC","BK4121","BK4232","CYRX","BK4082","BK4602","BK4099","BK4604","SCD","BK4588","BK4215","BK4022","MAA","BK4585","TM","SPRE","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661494","title":"Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661494","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661494?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist)Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340722/0/en/Structure-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","GDOC","LU0823414478.USD","NVIB","LU2294711713.HKD","BK4139","BK4009","CCO","GPCR","LU2357125470.USD","BK4539","BK4599","JDOC","LENZ","LU0823414551.USD","LU2249611893.SGD","BMED","HYLG","LU2506951792.HKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661430","title":"Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661430","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661430?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Ini","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340705/0/en/Trevi-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","IDNA","LENZ","BK4139","MEDX","BK4007","GDOC","BMED","RCC","BK4539","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657653126","title":"European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2657653126","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657653126?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:18","pubTimestamp":1786029491,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were heading higher late Thursday morning, rising 0.85% to 1,947.79 on the S&P Europe Select ADR Index.From continental Europe, the g","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EVAX","MREO","AFG","CRTO","BK4588","BBVA","SNN","LFGY","WPP","IEUR","BK4559","LU0889565916.HKD","PSO","BK4077","BK4207","CLLS","BK4568","LU0320765992.SGD","TRVG","ASND","WPP.AU","DGE.UK","BK4585","DEO","AUTL","BK4107","BK4139","BK4169","BK4117","NVIB","BK4009","BNTX","XBIX","OPRA","TRIB","MEDI","EPV","BK4023","BK4505","BK4535","BK4551","BK4082","BK4111","BDRX","BK4548","BK4204","IE00BFMHRM44.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657345566","title":"Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2657345566","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657345566?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:34","pubTimestamp":1786019640,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Aug.  06, 2026  (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/06/3340301/0/en/Celcuity-Schedules-Release-of-Second-Quarter-2026-Financial-Results-and-Webcast-Conference-Call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657460636","title":"Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657460636","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657460636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017600,"startTime":"0","endTime":"0","summary":"--  Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) ----  Completed sale of sevasemten and musc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BK4585","BK4007","BK4531","GDOC","EWTX","NVIB","IDNA","HCM","HYLG","BK4539","BMED","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","MRNX","MRNY","IBB","MEDI","IYH","TBXU","RSPH","GDOC","LFSC","PSCH","TECB","BBP","BMED","BK4585","GNMX","FRTY","XLVX","LABU","PINK","NVIB","SYNB","IEIH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657764305","title":"Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657764305","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657764305?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:05","pubTimestamp":1785960300,"startTime":"0","endTime":"0","summary":"Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes (“T2D”); data expected in the first quarter of 2027Enrollment also ongoing for th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339675/0/en/Biomea-Fusion-Reports-Second-Quarter-2026-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","GDOC","BMEA","HYLG","NVIB","BK4139","IDNA","JDOC","BK4539","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657678575","title":"OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2657678575","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657678575?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:05","pubTimestamp":1785873900,"startTime":"0","endTime":"0","summary":"-- Executing IND-enabling activities for next-generation PI3Kαpan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 -- Ho","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338800/0/en/OnKure-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","GDOC","BK4539","MEDX","IND","BK4139","BK4007","LENZ","HYLG","BMED","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656967554","title":"Corbus reports last patient completes last visit in CANYON-1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656967554","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656967554?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:55","pubTimestamp":1785851749,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals (CRBP) announced the last patient has completed their last clinical visit in the company’s CANYON-1 Phase 1b clinical trial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-reports-last-patient-completes-last-visit-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-reports-last-patient-completes-last-visit-in-canyon-1-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","NVIB","HYLG","BK4139","IDNA","CRBP","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656564305","title":"IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2656564305","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656564305?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:00","pubTimestamp":1785844800,"startTime":"0","endTime":"0","summary":"LAWRENCEVILLE, N.J., Aug.  04, 2026  (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338235/0/en/IMUNON-to-Hold-Second-Quarter-2026-Financial-Results-and-Business-Update-Conference-Call-on-Tuesday-August-11-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","MEDX","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304376","title":"Fresenius announces FDA approval of rituximab biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304376","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304376?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:15","pubTimestamp":1785788150,"startTime":"0","endTime":"0","summary":"Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","IDNA","LFSC","TBXU","IYH","IEIH","IBB","BK4196","BK4585","GNMX","MEDI","GDOC","BMED","PINK","LABU","NVIB","BBP","PSCH","FRTY","RSPH","MRNX","BK4588","XLVX","FSNUY","SYNB","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656078673","title":"ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656078673","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656078673?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:05","pubTimestamp":1785787500,"startTime":"0","endTime":"0","summary":"Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337877/0/en/ORIC-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Operational-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HYLG","NVIB","AR","BK4139","IDNA","ORIC","LNGX","MEDX","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656036803","title":"Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2656036803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656036803?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:32","pubTimestamp":1785774763,"startTime":"0","endTime":"0","summary":"Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. Xencor, Inc. is running a Phase 1 clinical trial called “A Phase 1, First-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xencors-xmab412-enters-first-in-human-testing-what-early-stage-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xencors-xmab412-enters-first-in-human-testing-what-early-stage-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GDOC","NVIB","IDNA","ISBC","BK4211","XNCR","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379121","title":"AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379121","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379121?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:33","pubTimestamp":1785760380,"startTime":"0","endTime":"0","summary":"Milestone Advances Ampligen Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027OCALA, Fla., Aug.  03, 2026  (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE Ame","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337516/29489/en/AIM-ImmunoTech-Ahead-of-Schedule-on-Last-Dose-DURIPANC-Critical-Clinical-Inflection-Point.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","GDOC","IDNA","HYLG","AIM","NVIB","BK4557","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379644","title":"Press Release: Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379644","media":"Dow Jones","labels":["executive","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379644?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:30","pubTimestamp":1785760200,"startTime":"0","endTime":"0","summary":"BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","R","BK4022","BK4139","BK4232","CUE","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379177","title":"Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379177","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379177?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:30","pubTimestamp":1785760200,"startTime":"0","endTime":"0","summary":"MIAMI, FL, Aug.  03, 2026  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/03/3337496/11676/en/Veru-to-Report-Fiscal-2026-Third-Quarter-Financial-Results-on-August-10th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4557","NVIB","IDNA","MEDX","HYLG","BK4007","GDOC","BK4183","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656766333","title":"Press Release: Design Therapeutics Provides Restore-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2656766333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656766333?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:00","pubTimestamp":1785758400,"startTime":"0","endTime":"0","summary":"RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1Cash and securities of $207.4 million at quarter-end provide strong financial runwayCARLSBAD, Calif., Aug. 03, 2026  -- Design Therapeutics, Inc. , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC portfolio.\"Design continued its strong operational execution in the second quarter building on the positive RESTORE-FA data reported in May. Those four-week data demonstrated the ability of DT-216P2 to increase endogenous frataxin and its potential to deliver a differentiated, best-in-disease therapy for Friedreich ataxia,\" said Pratik Shah, Ph.D., chairperson and chief ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HD","LU0238689110.USD","LU1496350171.SGD","BK4566","LU0820561818.USD","LU2461242641.AUD","BK4083","IE00BKVL7J92.USD","LU1069344957.HKD","LU1236620834.HKD","IE00BWXC8680.SGD","BK4581","IE00BZ1G4Q59.USD","LU1162221912.USD","LU0234572021.USD","R","LU2361045086.USD","LU0823434740.USD","MEDX","LU1551013342.USD","HYLG","LU0868494708.USD","LU1035775433.USD","LU1093756325.SGD","GDOC","LU1914381329.SGD","LU2756315318.SGD","IE00BSNM7G36.USD","LU2756315664.SGD","NVIB","SG9999001440.SGD","BK4550","LU0079474960.USD","HOMZ","BK4130","RTH","LU1929549753.HKD","LU2361044865.SGD","PKB","LU0868494617.USD","FA","LU0689472784.USD","BK4585","LU0820562030.AUD","DSGN","IE00B1XK9C88.USD","IE00B3T34201.USD","BK4022","LU1093756168.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656457133","title":"Recce Pharmaceuticals Seeks ASX Quotation for Advisory Fee Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2656457133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656457133?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:42","pubTimestamp":1785710561,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an announcement. Recce Pharmaceuticals Ltd., an Australian biotech company listed on the ASX...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recce-pharmaceuticals-seeks-asx-quotation-for-advisory-fee-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recce-pharmaceuticals-seeks-asx-quotation-for-advisory-fee-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655368936","title":"Press Release: Radiopharm Theranostics Reports Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655368936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655368936?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:00","pubTimestamp":1785495600,"startTime":"0","endTime":"0","summary":"endpoint, with 93% of patients treated with RAD 101 achieving concordance. with MRI imaging. Additionally, an interim analysis of 14 patients from. -- The Company anticipates the initiation of a Phase 3, multi-center,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK7067","MEDX","BK4183","BK4139","ODD","IDNA","GDOC","RAD.AU","RADX","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":7,"totalSize":170,"code":"91000000","status":"200"}]}}